Skip to main content
Premium Trial:

Request an Annual Quote

Biocept Target Selector BRAF RUO Kits

Biocept has launched a Target Selector research-use-only molecular assay for the detection of BRAF mutations in both formalin-fixed, paraffin-embedded samples and blood samples. The kits use the company's Switch-Blocker technology to enrich the specimen for mutations of interest, resulting in ultra-high assay sensitivity and specificity. Biocept said that in general, its Target Selector kits can detect mutations of interest in circulating tumor DNA at a level of one mutant copy in 10,000 wildtype molecules. The assays can be used with a variety of analytical platforms including qPCR, Sanger sequencing, next generation sequencing, microarrays, and mass spectrometry. The new BRAF kit complements the company's previously launched EGFR mutation-detection assay.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.